Human Parathyroid Hormone (PTH) ELISA

Features

• RUO
• assay for the in vitro quantitative measurement of human Intact Parathyroid Hormone (PTH) in serum and plasma
• limit of detection 0.8 pg/ml

Research topic

Bone and cartilage metabolism, Oncology

Summary

Human parathyroid hormone (hPTH) is a major physiological regulator of phosphocalcic metabolism. hPTH increases serum calcium concentrations by its actions on kidney (enhancing tubular Ca++ reabsorption and phosphate excretion) and bone (stimulating osteoclastic activity and bone resorption). It indirectly affects intestinal absorption of Ca++ by stimulating renal 1αhydroxylation of 25 hydroxyvitamin D. The release of PTH is controlled in a negative feedback loop by the serum concentration of Ca++. PTH is synthesized in the chief cells of the parathyroid glands and secreted as an 84 amino acid molecule called "intact PTH", which is the main bioactive product. This molecule is degraded by proteolytic cleavage between amino acids 33-37 at peripheral sites to form biologically active amino- terminal fragments and biologically inactive carboxyl-terminal fragments. The carboxylterminal fragments are cleared only by glomerular filtration, while the bioactive intact PTH and amino-terminal fragments are also metabolically degraded in the liver and other tissues. The halflife of the carboxyl- terminal fragments increases dramatically in patients with renal failure. Thus, the measurement of intact PTH correlates best with the hormone production and biological activity.

Clinical application The measurement of intact hPTH is used to establish the diagnosis of primary hyperparathyroidism by demonstrating elevated serum levels of bioactive PTH. It allows documenting the occurrence of secondary hyperparathyroidism in patients with Vit.D deficiency, intestinal malabsorption, or renal failure. In this last situation, the absence of interference with the inactive carboxyl-terminal fragments is especially valuable. The specificity and high sensitivity of the assay also allows differentiating clearly low serum PTH levels in hypoparathyroidism or in tumor-induced hypercalcaemia.